Indication
In combination with other pulmonary arterial hypertension (PAH) therapies for the treatment of PAH in adult patients with WHO Functional Class (FC) II to III, to improve exercise capacity.
Medicine details
- Medicine name:
- sotatercept (Winrevair)
- SMC ID:
- smc2831
- Pharmaceutical company
- Merck Sharp & Dohme Ltd
- BNF chapter
- Cardiovascular system
- Submission type
- Full
- Publication due date:
- 09 February 2026
- SMC meeting date:
- 13 January 2026
- Patient group submission deadline:
- TBC